Prof. Tormod Fladby

 

•Head of Department of Neurology, AHUS.

•Professor II, Institute of Clinical Medicine, University of Oslo

He is a professor of Neurology with tenure at Oslo University (UiO), senior consultant and head of the Department of Neurology at Akershus University Hospital.

Prof. Fladby's own main research interest is cognitive impairment and dementia. He has established a memory clinic and a research group working in this area with the stated ultimate goal of contributing to the implementation of disease-modifying treatment for these conditions.

Towards this purpose, we have established a multi-modal and network-based approach to research questions. He leads the Norwegian “national arm” of the first EU / JPND project, BIOMARKADPD, encompassing leading clinical groups at all Norwegian University Hospitals and the "Dementia Disease Initiation", a trans-regional Norwegian national group encompassing the same university hospitals and also other nationat and international initiatives.

He has led the clinical department of neurology at Ahus for 8 years, this has expanded both with respect to R&D activity and clinically, to a 72-bed, multidisciplinary (neuropsychology, neurophysiology, neurology, molecular biology etc) multi-section (stroke, neurorehabilitation, general neurology including separate units for the major neurologic diseases etc. and memory unit) department with close to 200 employees (whereof 41 doctors) R&D. The R&D activity is organized within the Clinical Neuroscience Group at Ahus (CNG). Whereas direct leadership within the clinical sections within the epartment is delegated, he personally lead the CNG and all clinical section leaders report to him.

In this position we have emphasized fruitfull collaboration with pharmaceutical industry, and he has been national PI for phase 1 and phase 2 studies (GSK).

Publications:

van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, Bonanni L, Lemstra AW; European DLB consortium (2016). Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. J Alzheimers Dis. 2016 Aug 18;54(1):287-95. doi: 10.3233/JAD-160322.

Lillenes MS, Rabano A, Støen M, Riaz T, Misaghian D, Møllersen L, Esbensen Y, Günther CC, Selnes P, Stenset VT, Fladby T, Tønjum T (2016). Altered DNA base excision repair profile in brain tissue and blood in Alzheimer's disease. Mol Brain. 2016 May 28;9(1):61. doi: 10.1186/s13041-016-0237-z.

Henjum K, Almdahl IS, Årskog V, Minthon L, Hansson O, Fladby T, Nilsson LN (2016). Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimers Res Ther. 2016 Apr 27;8(1):17. doi: 10.1186/s13195-016-0182-1.

Hessen E, Stav AL, Auning E, Selnes P, Blomsø L, Holmeide CE, Johansen KK, Eliassen CF, Reinvang I, Fladby T, Aarsland D (2016). Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases. J Parkinsons Dis. 2016 Apr 2;6(2):413-21. doi: 10.3233/JPD-150761.

Kalheim LF, Bjørnerud A, Fladby T, Vegge K, Selnes P (2016). White matter hyperintensity microstructure in amyloid dysmetabolism. J Cereb Blood Flow Metab. 2016 Jan 20. pii: 0271678X15627465. [Epub ahead of print] (Level 2).

Stav AL, Johansen KK, Auning E, Kalheim LF, Selnes P, Bjørnerud A, Hessen E, Aarsland D, Fladby T (2016). Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson’s disease: a cross-sectional study. J Parkinsons Dis. 10.1038/npjparkd.2015.30.

Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJ, Blennow K, Chiasserini D, Engelborghs S, Fladby T, Genc S, Kruse N, Kuiperij HB, Kulic L, Lewczuk P, Mollenhauer B, Mroczko B, Parnetti L, Vanmechelen E, Verbeek MM, Winblad B, Zetterberg H, Koel-Simmelink M, Teunissen CE (2015). A Practical Guide to Immunoassay Method Validation. Front Neurol. 2015 Aug 19;6:179. doi: 10.3389/fneur.2015.00179.

Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T, Aarsland D (2015). Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. J Parkinsons Dis. 2015 Nov 23;5(4):783-92. doi: 10.3233/JPD-150682.

Røgeberg M, Almdahl IS, Wettergreen M, Nilsson LNG, Fladby T (2015). Isobaric quantification of CSF amyloid beta peptides in Alzheimer’s disease – C-terminal truncation relates to early measures of neurodegeneration. J Proteome Res. 2015 Nov 6;14(11):4834-43. doi: 10.1021/acs.jproteome.5b00668 (Level 2).

Reijs BL, Teunissen CE, Goncharenko N, Betsou F, Blennow K, Baldeiras I, Brosseron F, Cavedo E, Fladby T, Froelich L, Gabryelewicz T, Gurvit H, Kapaki E, Koson P, Kulic L, Lehmann S, Lewczuk P, Lleó A, Maetzler W, de Mendonça A, Miller AM, Molinuevo JL, Mollenhauer B, Parnetti L, Rot U, Schneider A, Simonsen AH, Tagliavini F, Tsolaki M, Verbeek MM, Verhey FR, Zboch M, Winblad B, Scheltens P, Zetterberg H, Visser PJ (2015). The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Front Neurol. 2015 Oct 15;6:216. doi: 10.3389/fneur.2015.00216.

Hessen E, Nordlund A, Stålhammar J, Eckerström M, Bjerke M, Exkerström C, Göthlin M, Fladby T, Reinvang I, Wallin A (2015). T-Tau is associated with objective memory decline over two years in persons seeking help for subjective cognitive decline: A report from the Gothenburg-Oslo MCI study. Journal of Alzheimer’s Disease. In press

Kruse N, Persson S, Alcolea D, Bahl JM, Baldeiras I, Capello E, Chiasserini D, Bocchio Chiavetto L, Emersic A, Engelborghs S, Eren E, Fladby T, Frisoni G, García-Ayllón MS, Genc S, Gkatzima O, Heegaard NH, Janeiro AM, Kováčech B, Kuiperij HB, Leitão MJ, Lleó A, Martins M, Matos M, Mollergard HM, Nobili F, Öhrfelt A, Parnetti L, de Oliveira CR, Rot U, Sáez-Valero J, Struyfs H, Tanassi JT, Taylor P, Tsolaki M, Vanmechelen E, Verbeek MM, Zilka N, Blennow K, Zetterberg H, Mollenhauer B (2015). Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiol Aging. 36(9):2587-96. doi: 10.1016/j.neurobiolaging.2015.05.003

Selnes P, Grambaite R, Rincon M, Bjørnerud A, Gjerstad L, Hessen E, Auning E, Johansen K, Almdahl IS, Due-Tønnessen P, Vegge K, Bjelke B, Fladby T (2015). Hippocampal complex atrophy in poststroke and mild cognitive impairment. J Cereb Blood Flow Metab. doi: 10.1038/jcbfm.2015.110 (Level 2)

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ; Amyloid Biomarker Study Group, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rüther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H (2015). Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 313(19):1924-38. doi: 10.1001/jama.2015.4668 (Level 2)

Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T (2015). Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. Parkinsonism Relat Disord. 21(7):758-64. doi: 10.1016/j.parkreldis.2015.04.027

Eliassen CF, Selnes P, Selseth Almdahl I, Reinvang I, Fladby T, Hessen E (2015). Hippocampal Subfield Atrophy in Multi-Domain but Not Amnestic Mild Cognitive Impairment. Dement Geriatr Cogn Disord. 40(1-2):44-53. doi: 10.1159/000381142

Zayats T, Athanasiu L, Sonderby I, Djurovic S, Westlye LT, Tamnes CK, Fladby T, Aase H, Zeiner P, Reichborn-Kjennerud T, Knappskog PM, Knudsen GP, Andreassen OA, Johansson S, Haavik J (2015). Genome-wide analysis of attention deficit hyperactivity disorder in Norway. PLoS One. 10(4):e0122501. doi: 10.1371/journal.pone.0122501

Rogeberg M, Wettergreen M, Nilsson LN, Fladby T (2015). Identification of amyloid beta mid-domain fragments in human cerebrospinal fluid. Biochimie. 113:86-92. doi: 10.1016/j.biochi.2015.03.022.

Desikan RS, Schork AJ, Wang Y, Thompson WK, Dehghan A, Ridker PM, Chasman DI, McEvoy LK, Holland D, Chen CH, Karow DS, Brewer JB, Hess CP, Williams J, Sims R, O'Donovan MC, Choi SH, Bis JC, Ikram MA, Gudnason V, DeStefano AL, van der Lee SJ, Psaty BM, van Duijn CM, Launer L, Seshadri S, Pericak-Vance MA, Mayeux R, Haines JL, Farrer LA, Hardy J, Ulstein ID, Aarsland D, Fladby T, White LR, Sando SB, Rongve A, Witoelar A, Djurovic S, Hyman BT, Snaedal J, Steinberg S, Stefansson H, Stefansson K, Schellenberg GD, Andreassen OA, Dale AM; Inflammation Working Group and International Genomics of Alzheimer’s Disease Project (IGAP) and DemGene Investigators (2015). Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. Circulation. 131(23):2061-9. doi: 10.1161/CIRCULATIONAHA.115.015489 (Level 2)

Schmidt R, Hofer E, Bouwman FH, Buerger K, Cordonnier C, Fladby T, Galimberti D, Georges J, Heneka MT, Hort J, Laczó J, Molinuevo JL, O'Brien JT, Religa D, Scheltens P, Schott JM, Sorbi S (2015). EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease. Eur J Neurol. 22(6):889-98. doi: 10.1111/ene.12707 (Level 2)

Steinberg S, Stefansson H, Jonsson T, Johannsdottir H, Ingason A, Helgason H, Sulem P, Magnusson OT, Gudjonsson SA, Unnsteinsdottir U, Kong A, Helisalmi S, Soininen H, Lah JJ; DemGene, Aarsland D, Fladby T, Ulstein ID, Djurovic S, Sando SB, White LR, Knudsen GP, Westlye LT, Selbæk G, Giegling I, Hampel H, Hiltunen M, Levey AI, Andreassen OA, Rujescu D, Jonsson PV, Bjornsson S, Snaedal J, Stefansson K (2015). Loss-of-function variants in ABCA7 confer risk of Alzheimer’s disease. Nature Genetics 47(5):445-7 doi: 10.1038/ng.3246 (Level 2)

Andreasen N, Simeoni M, Ostlund H, Lisjo PI, Fladby T, Loercher AE, Byrne GJ, Murray F, Scott-Stevens PT, Wallin A, Zhang YY, Bronge LH, Zetterberg H, Nordberg AK, Yeo AJ, Khan SA, Hilpert J, Mistry PC (2015). First administration og the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer’s disease: a randomized, placebo-controlled study. PloS One. 10(3):e0098153. doi: 10.1371/journal.pone.0098153.

Desikan RS, Schork AJ, Wang Y, Witoelar A, Sharma M, McEvoy LK, Holland D, Brewer JB, Chen CH, Thompson WK, Harold D, Williams J, Owen MJ, O'Donovan MC, Pericak-Vance MA, Mayeux R, Haines JL, Farrer LA, Schellenberg GD, Heutink P, Singleton AB, Brice A, Wood NW, Hardy J, Martinez M, Choi SH, DeStefano A, Ikram MA, Bis JC, Smith A, Fitzpatrick AL, Launer L, van Duijn C, Seshadri S, Ulstein ID, Aarsland D, Fladby T, Djurovic S, Hyman BT, Snaedal J, Stefansson H, Stefansson K, Gasser T, Andreassen OA, Dale AM (2015). Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the MAPT locus. Mol Psychiatry. doi: 10.1038/mp.2015.6 (Level 2)

Auning E, Selnes P, Grambaite R, Šaltytė Benth J, Haram A, Løvli Stav A, Bjørnerud A, Hessen E, Hol PK, Muftuler løndalen A, Fladby T, Aarsland D (2014). Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment. Acta Psychiatrica Scandinavica. 131(2):139-147. doi: 10.1111/acps.12352 (Level 2)

Haram A, Hessen E, Auning E, Stav AL, Boeve BF, Eliassen CF, Rugland E, Esnaashari A, Fladby T & Aarsland D (2014). Clinical Correlates of RBD in Early Parkinson Disease. Journal of Alzheimers Disease & Parkinsonism. doi: 10.4172/2161-0460.1000174

Rogeberg M, Furlund CB, Moe MK, Fladby T (2014). Identification of peptide products from enzymatic degradation of amyloid beta. Biochimie 105:216-20. doi: 10.1016/j.biochi.2014.06.023

Hessen E, Reinvang I, Eliassen CF, Nordlund A, Gjerstad L, Fladby T, Wallin A (2014). The Combination of Dysexecutive and Amnestic Deficits Strongly Predicts Conversion to Dementia in Young Mild Cognitive Impairment Patients: A Report from the Gothenburg-Oslo MCI Study. Dementia and geriatric cognitive disorders extra. 4(1):76-85. doi: 10.1159/000360282

Auning E, Kjærvik VK, Selnes P, Aarsland D, Haram A, Bjørnerud A, Hessen E, Esnaashari A, Fladby T (2014). White matter integrity and cognition in Parkinson's disease: A cross-sectional study. BMJ Open. 4(1):e003976. doi: 10.1136/bmjopen-2013-003976

Grambaite R, Hessen E, Auning E, Aarsland D, Selnes P, Fladby T (2013). Correlates of subjective and mild cognitive impairment: Depressive symptoms and CSF biomarkers. Dementia and geriatric cognitive disorders extra. 3(1):291-300. doi: 10.1159/000354188

Coello C, Willoch F, Selnes P, Gjerstad L, Fladby T, Skretting A (2013). Correction of partial volume effect in 18F-FDG PET brain studies using coregistered MR volumes: Voxel based analysis of tracer uptake in the white matter. NeuroImage. 72:183-92. doi: 10.1016/j.neuroimage.2013.01.043 (Level 2)

Selnes P, Aarsland D, Bjørnerud A, Gjerstad L, Wallin A, Hessen E, Reinvang I, Grambaite R, Auning E, Kjærvik VK, Due-Tønnessen P, Stenset V, Fladby T (2013). Diffusion Tensor Imaging Surpasses Cerebrospinal Fluid as Predictor of Cognitive Decline and Medial Temporal Lobe Atrophy in Subjective Cognitive Impairment and Mild Cognitive Impairment. Journal of Alzheimer's Disease. 33(3):723-36. doi: 10.3233/JAD-2012-121603

Amlien IK, Fjell AM, Walhovd KB, Selnes P, Stenset V, Grambaite R, Bjørnerud A, Due-Tønnessen P, Skinningsrud A, Gjerstad L, Reinvang I, Fladby T (2013). Mild cognitive impairment: cerebrospinal fluid tau biomarker pathologic levels and longitudinal changes in white matter integrity. Radiology. 266(1):295-303. doi: 10.1148/radiol.12120319

Selnes P, Fjell AM, Gjerstad L, Bjørnerud A, Wallin A, Due-Tønnessen P, Grambaite R, Stenset V, Fladby T (2012). White matter imaging changes in subjective and mild cognitive impairment. Alzheimer's & Dementia. 8(5 Suppl):S112-21. doi: 10.1016/j.jalz.2011.07.001

Sorbi S, Hort J, Erkinjuntti T, Fladby T, Gainotti G, Gurvit H, Nacmias B, Pasquier F, Popescu BO, Rektorova I, Religa D, Rusina R, Rossor M, Schmidt R, Stefanova E, Warren JD, Scheltens P; EFNS Scientist Panel on Dementia and Cognitive Neurology (2012). EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. European Journal of Neurology. 19(9):1159-79. doi: 10.1111/j.1468-1331.2012.03784.x (Level 2)

Auning E, Rongve A, Fladby T, Booij J, Hortobágyi T, Siepel FJ, Ballard C, Aarsland D (2011). Early and Presenting Symptoms of Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders. 32(3):202-8. doi: 10.1159/000333072

Skogseth RE, Fladby T, Mulugeta E, Aarsland D (2011). Biomarkører i spinalvæske ved demens. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 131(22):2235-8 . doi: 10.4045/tidsskr.10.0104

Aarsland D, Rongve A, Fladby T, Testad I, Kivipelto M, Winblad B (2011). Nye diagnosekriterier for Alzheimers sykdom. Tidsskrift for Den norske legeforening. 131(22):2224-5 doi: 10.4045/tidsskr.11.1028